Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL.
Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject’s baseline, which triggered transvaginal ultrasound. Specificity and PPV were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/625973 |
| Date | 31 January 2017 |
| Creators | Skates, Steven J, Greene, Mark H., Buys, Saundra S, Mai, Phuong L, Brown, Powel, Piedmonte, Marion, Rodriguez, Gustavo, Schorge, John O, Sherman, Mark, Daly, Mary B, Rutherford, Thomas, Brewster, Wendy R, O'Malley, David M, Partridge, Edward, Boggess, John, Drescher, Charles W, Isaacs, Claudine, Berchuck, Andrew, Domchek, Susan, Davidson, Susan A, Edwards, Robert, Elg, Steven A, Wakeley, Katie, Phillips, Kelly-Anne, Armstrong, Debroah, Horowitz, Ira, Fabian Carol J, Walker, Joan, Sluss, Patrick M, Welch, William, Minasian, Lori, Horick, Nora K, Kasten, Carol H, Nayfield, Susan, Alberts, David, Finkelstein, Dianne M, Lu, Karen H |
| Contributors | Massachusetts General Hospital, Boston, MA, National Cancer Institute, Rockville, MD, Huntsman Cancer Institute, University of Utah, School of Medicine, Salt Lake City, UT, MD Anderson Cancer Center, Houston, TX, Roswell Park Cancer Institute, Buffalo, NY, NorthShore University Health System, Evanston, IL, Fox Chase Cancer Center, Philadelphia, PA, University of South Florida, Tampa, FL, University of North Carolinia, Chapel Hill, NC, Ohio State University and the James Cancer Center, Columbus, OH, University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL, Rex Cancer Center, Raleigh, NC, Fred Hutchinson Cancer Research Center, Seattle, WA, Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC, Duke University Medical Center, Division of Gynecologic Oncology, Durham, NC, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Denver Health Medical Center, Denver, CO, Magee-Womens Hospital, Pittsburgh, PA, The Iowa Clinic, Gynecologic Oncology, Des Moines, IA, Dana-Farber Cancer Center in Clinical Affiliation with South Shore Hospital, South Weymouth, MA, Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, Emory University School of Medicine, Atlanta, GA, The University of Kansas Cancer Center, Westwood, KS, Stephenson Cancer Center, University of Oklahoma HSC, Oklahoma City, OK, Brigham and Women's Hospital, Boston, MA, Food and Drug Administration, Silver Spring, MD, University of Florida, Gainseville, FL, University of Arizona Cancer Center, Tucson, AZ |
| Publisher | American Association for Cancer Research |
| Source Sets | University of Arizona |
| Language | English |
| Detected Language | English |
| Type | Article |
| Rights | Copyright © 2017, American Association for Cancer Research |
Page generated in 0.0029 seconds